Post-COVID-19 resurgence of respiratory viruses in Taiwan: an interrupted time series analysis from three regional medical centers (2015-2023)

台湾地区新冠疫情后呼吸道病毒的再次爆发:来自三个区域医疗中心的间断时间序列分析(2015-2023)

阅读:2

Abstract

BACKGROUND: The COVID-19 pandemic and associated nonpharmaceutical interventions (NPIs) profoundly disrupted the transmission dynamics of respiratory viruses worldwide. However, the long-term impact on multiple respiratory pathogens, particularly in Taiwan, remains unclear. METHODS: We conducted an interrupted time series analysis using negative binomial regression to assess monthly trends of five respiratory viruses—adenovirus, enterovirus, influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV)—on the basis of data collected from three tertiary medical centers in Taiwan (2015–2023). The study period was divided into three phases: pre-COVID-19 (2015–2019), during COVID-19 (2020–2022), and post-COVID-19 (2023). Negative binomial regression with seasonal adjustment and lag variables was used to assess virus-specific trends. Percentage changes in case numbers were calculated. RESULTS: A total of 60,368 virus cases were identified. During the COVID-19 period, significant decreases in the number of adenovirus (-31.6%), enterovirus (-67.1%), and influenza (-85.0%) cases were observed. Postpandemic, the number of enterovirus and influenza cases rebounded sharply, with increases of 499.3% and 619.5%, respectively. PIV and adenovirus cases also increased by 223.8% and 151.2%, respectively. In contrast, the number of RSV cases did not significantly change during the study period. However, RSV exhibited altered seasonal patterns and atypical peaks during and after the pandemic. CONCLUSION: The COVID-19 pandemic led to substantial disruptions in respiratory virus circulation in Taiwan, followed by divergent rebound patterns postpandemic. Our findings highlight the complex interplay between public health interventions and viral epidemiology. Continued surveillance is vital for understanding future transmission patterns and informing preparedness strategies. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-025-11930-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。